Short Reads

Dissemination of misleading information on the safety of a medical product can be a "by object" infringement

Dissemination of misleading information on the safety of a medical pr

Dissemination of misleading information on the safety of a medical product can be a "by object" infringement

01.02.2018 NL law

On 23 January 2018, the European Court of Justice delivered its judgment on a request for a preliminary ruling by the Italian Council of State. The request concerned an agreement between Roche and Novartis to make public statements concerning the alleged lack of safety and efficacy of one of Roche's products which competed with a product licensed to Novartis (the Agreement). The Court of Justice found that such an agreement can, under specific circumstances, constitute a restriction of competition "by object".

Genentech, a subsidiary of Roche, developed bevacizumab (Avastin) and ranibizumab (Lucentis). Avastin was developed to treat certain types of cancer. Lucentis was specifically developed to treat ocular diseases. Genentech licensed Avastin to its parent Roche and, since Roche was not active in the ophthalmological field, it licensed Lucentis to Novartis.

Prior to the market launch of Lucentis in Italy, doctors started prescribing the oncological drug Avastin as a treatment for eye diseases, despite the fact that such use was not included in Avastin's marketing authorisation (off-label use). Given its lower price, the off-label use of Avastin continued well after the market launch of Lucentis.

The Italian Competition Authority (ICA) had found that, following the market launch of Lucentis, Roche and Novartis (the Parties) entered into an agreement with the aim to artificially differentiate between Avastin and Lucentis by exaggerating the risks associated with the off-label use of Avastin while claiming that Lucentis had a better safety profile. According to the ICA, these statements were made without sufficient scientific evidence. The Parties intended to use this Agreement to prevent the further expansion of Aventis in the ophthalmological field and to promote Lucentis instead. According to the ICA, the Agreement intended to unlawfully maximise the profits of the Parties by promoting the most expensive product, namely Lucentis. Consequently, the ICA found that the Parties had entered into a market-sharing agreement, which constitutes a restriction of competition "by object".

The Parties challenged the decision of the ICA before the Italian Council of State, which referred the case for a preliminary ruling to the Court of Justice. The key issue before the Court of Justice was whether an arrangement between competing undertakings to disseminate unconfirmed scientific information on the off-label use of one of their products, with the aim or reducing the competitive pressure exerted on the other product, could constitute a restriction of competition "by object".

The Court first established that medicines that have a marketing authorisation (MA) for a specific indication and medicines used off-label for the same indication can, under circumstances, actually compete in same relevant market.

Next, the Court found, siding with the Advocate General's opinion, that the Agreement could indeed be considered a "by object" restriction of competition. First, the Court emphasized that the responsibility to report any potential adverse effects to the authorities and consequently to professionals and the general public lies with the MA holder alone and not with another company marketing a competing product under a separate MA. In this case, it was not only the MA holder, i.e. Roche, that had been involved in the relevant communications but also Novartis. According to the Court, this provides an indication that the communications may not have been solely driven by objectives related to pharmacovigilance. 

Secondly, the Court found that if the information shared by the Parties was misleading, then the Agreement should be considered a "by object" infringement. The Court held that such information should be considered as misleading if– in short – it was shared with the purpose of confusing the relevant authorities on the safety profile of Avastin so they would include in its summary of characteristics the alleged adverse reactions, which would then allow Roche to launch a communication campaign in which the safety risks could be exaggerated vis-à-vis doctors and the general public. The Court left this assessment to the Italian Court.

This case is important as it effectively marks the introduction of the doctrine of disparagement in EU competition law. Similar cases (see Sanofi-Aventis decision) have been pursued in France where the competition authority found – and courts have confirmed – that the dissemination of misleading information about a pharmaceutical product's characteristics can infringe competition rules.

This article was published in the Competition Law Newsletter of January 2018. Other articles in this newsletter:

  1. Qualifying dawn raid documents as 'in scope' or 'out of scope': marginal review by Belgian Court
  2. Highest German Court rules that ASICS's ban on using price comparison websites violates EU competition law

Team

Related news

14.08.2019 BE law
Verklaring van openbaar nut is geen "project" in de zin van de MER-regelgeving

Articles - In een recent arrest bevestigt de Raad van State dat "verklaringen van openbaar nut", bedoeld in artikel 10 van de wet van 12 april 1965 betreffende het vervoer van gasachtige produkten en andere door middel van leidingen niet onder het begrip "project" uit de project-MER-regelgeving valt. Of hetzelfde geldt voor elk type gelijkaardige administratieve toelating, is daarmee evenwel nog niet gezegd. Niettemin geeft de Raad met zijn arrest een belangrijk signaal dat niet elke mogelijke toelating onder de project-MER-regelgeving valt.

Read more

01.08.2019 NL law
Brand owners beware: Commission tough on cross-border sales restrictions

Short Reads - The European Commission recently imposed a EUR 6.2 million fine on Hello Kitty owner Sanrio for preventing its licensees from selling licensed merchandising products across the entire EEA. Sanrio is the second licensor (after Nike) to be fined for imposing territorial sales restrictions on its non-exclusive licensees for licensed merchandise. A third investigation into allegedly similar practices by Universal Studios is ongoing. The case confirms the Commission's determination to tackle these practices, regardless of type or form.

Read more

08.08.2019 BE law
Regulating online platforms: piece of the puzzle

Articles - The new Regulation no. 2019/1150 of the European Parliament and of the Council of 20 June 2019 on promoting fairness and transparency for business users of online intermediation services, applicable as of 12 July 2020, is another piece of the puzzle regulating online platforms, this time focussing on the supply side of the platforms.

Read more

01.08.2019 NL law
Call of duty: Commission must state reasons when straying from its guidelines

Short Reads - The European Commission has lost a second battle concerning its EUR 15 million fine imposed upon interdealer broker ICAP, this time before the European Court of Justice. The Court upheld the previous judgment of the General Court on the basis of the Commission's failure to state reasons concerning its fining methodology of cartel facilitator ICAP. This may lead to more reasoned Commission decisions in the future - deterrence of cartel behaviour does not justify keeping the methodology for setting the fines as a 'black box'.

Read more

01.08.2019 NL law
General court dismisses all five appeals in the optical disk drives cartel

Short Reads - The General Court recently upheld a Commission decision finding that suppliers of optical disk drives colluded in bids for sales to Dell and HP by engaging in a network of parallel bilateral contacts over a multi-year period. The General Court rejected applicants' arguments regarding the Commission's fining methodology, including that the Commission ought to have provided reasons for not departing from the general methodology set out in its 2006 Guidelines.

Read more

22.07.2019 NL law
HagaZiekenhuis beboet voor datalek

Short Reads - Enkele maanden geleden vierden we de eerste verjaardag van de Algemene Verordening Gegevensbescherming (AVG) met een uitgebreide beschouwing  over de belangrijkste  ontwikkelingen uit  het eerste jaar van de verordening. We concludeerden daarin onder meer dat de door sommigen voorspelde hoge bestuurlijke boetes voor overtredingen van de AVG tot dan toe  - zowel in Nederland als in de andere EU-lidstaten - grotendeels waren uitgebleven.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring